Amytracker is used to shed light on Protein Aggregation in Parkinson’s Disorder

Amytracker is used to shed light on Protein Aggregation in Parkinson’s Disorder

Molecular protein chaperons are known for their role in preventing protein misfolding and aggregation. However, a paper published in the journal Acta Neuropathologica showed that there might be more to it. In the paper, Rachel E. Lackie and colleagues found that STI1 (a co-chaperon) directly interacts with the α-synuclein and enhances aggregation. They found that in Parkinson’s disorder conditions the expression level of STI1 and Hsp90 pair (chaperon and co-chaperon) is elevated and causes increased aggregation of α-synuclein and its S129 phosphorylation (psyn129).

Image: 🔬Characterization of WT human α-synuclein PFFs (Performed filaments) and pathology induced in M83+/- mice. pSyn129 (red) and Amytracker (green). Top row - M83+/- mice brain section without PFF, bottom row with PFF. Lackie at al. (Fig. Sup S2) (CC-BY-4.0)